Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma

Alencar, Alvaro J.; Hirayama, Alexandre V.; Clé, Diego V.; Salvino, Marco Aurélio; Perini, Guilherme Fleury; Arrais, Celso; Baiocchi, Otavio C. G.; Palma, Leonardo Carvalho; Colturato, Iago; Vaz, Jorge Faria; Chiattone, Ricardo; Lima, Marcos de; Filho, Jayr Schmidt; Nabhan, Samir Kanaan; Rocha, Vanderson; Cunha, Renato; Chiattone, Carlos S.

doi:10.1016/j.htct.2021.09.003

Hematology, Transfusion and Cell Therapy

2021

DOI: 10.1016/j.htct.2021.09.003

|View full text |Cite

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma

Alvaro J. Alencar

Alexandre V. Hirayama

Diego V. Clé

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 46 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

CAR T-cell therapy and the onco-nephrologist

Salvino,

Mussetti,

Peña

et al. 2024

Front. Nephrol.

View full text Add to dashboard Cite

Cell therapy, specifically the revolutionary chimeric antigen receptor (CAR) T-cell therapy, has transformed the landscape of oncology, making substantial strides in practical treatment approaches. Today, established guidelines for diseases such as lymphomas, myelomas, and leukemias actively advocate the utilization of these once-unconventional therapies. The practical impact of these therapies is underscored by their unparalleled efficacy, reshaping the way we approach and implement treatments in the realm of oncology. However, CAR T-cell therapy, with its performance in anti-tumor aggression through cellular action and inflammatory response, also comes with various adverse events, one of which is kidney injury. Therefore, the management of these side effects is extremely important. The integration of knowledge between oncologists and specialized nephrologists has led to the emergence of a new sub-area of expertise for onco-nephrologists specializing in managing kidney complications from immune effector therapies.

show abstract

CAR T-cell therapy and the onco-nephrologist

Salvino,

Mussetti,

Peña

et al. 2024

Front. Nephrol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma

Cited by 1 publication

References 46 publications

CAR T-cell therapy and the onco-nephrologist

CAR T-cell therapy and the onco-nephrologist

Contact Info

Product

Resources

About